XTLB
XTL Biopharmaceuticals
XTLB
XTLB
5 hedge funds and large institutions have $282K invested in XTL Biopharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$80.3K |
| 2 |
CTC
2
Central Trust Company
Jefferson City,
Missouri
|
$203 |
Top Sellers
| 1 |
1
UBS Group
Zurich,
Switzerland
|
$55 |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $201K | 198,888 | – | – |
|
|
2
Morgan Stanley
New York
| $80.3K | 79,542 | +38,971 | +96% |
|
3
BNP Paribas Financial Markets
Paris,
France
| $303 | 300 | – | – |
|
|
CTC
4
Central Trust Company
Jefferson City,
Missouri
| $203 | 200 | +200 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $55 | 54 | -66 | -55% |
|
|
CFGS
6
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|